BIVI News and Press, BioVie Inc. From 03/02/23

CARSON CITY, Nev., March 02, 2023 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver di...

CARSON CITY, Nev., Feb. 21, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease,...

Summary BioVie came out with phase 2 data in December. BIVI stock went up a lot, then fell equally badly, after that. The Company has very little cash. BioVie ( BIVI ) announced data from multiple phase 2 trials in December, went up hugely, but today it is down 60%. BI...

Summary The treatment of Moderate Alzheimer's disease requires intervention after the over-activation of NMDA receptors. BioVie does this by reducing the phosphorlyation of ERK (Extracellular Regulatory Kinase) and by inhibiting NF-kB (Nuclear Factor-kappa Beta). Panax ginseng does ...

ORLANDO, FL / ACCESSWIRE / January 25, 2023 / RedChip Companies is pleased to announce its CEO, Dave Gentry, was recently welcomed as a member of the Forbes Business Council. The Forbes Business Council committee invited Gentry to join the elite group of business leaders in recognition of his p...

Summary BioVie’s pipeline indications represent a combined addressable market size of more than $100 billion with high unmet medical needs. Phase 2 trials have provided evidence to indicate that NE3107 may improve cognition and function in Alzheimer's disease and dementia and may...

Shares of biotech BioVie (NASDAQ: BIVI) rose 15.3% in December, according to data provided by S&P Global Market Intelligence . The stock closed November at $6.74 a share. It climbed to as high as $14.38 on Dec. 16, before closing the month at $7.77. That roller-coaster climb c...

Summary Over the past few months, BioVie has reported good data from a Phase 2 trial in Alzheimer’s and a Phase 2 placebo-controlled Parkinson’s disease trial. The Phase 3 trial in Alzheimer’s is ongoing. Focusing on some of the trial’s endpoints, I set o...

NEW YORK, NY / ACCESSWIRE / December 13, 2022 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap publicly traded companies recently issued a new C-Level interview with BioVie. Toni had the pleasure of recently conducting the Inter...

BioVie ( NASDAQ: BIVI ), which has been on a tear since releasing additional data from a Phase 2 trial for its Alzheimer's candidate NE3107 on Tuesday, is closed up 54% Wednesday. The stock is up ~76% since Monday's close. An analysis of blood samples showed a potential i...